BCL6 expression is modest in TKI-naive CML cells, but it is substantially increased in CML cell lines and primary CD34+ cells after TKI therapy, although its function in CML is unknown (Hurtz et al., 2011). Here, BCL6 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.